Behind the Eye Drug Development

January 19, 2015

CfPA-The Center for Professional Advancement, 90 Minute Accredited Online Training
February 10, 2015 at 11:00 a.m.–12:30 p.m. (ET)

Who Should Attend?
This online training will benefit the following industries: pharmaceutical, biologic and medical device where a therapeutic is being devised for treatment of an ocular disease that occurs in the posterior fundus of the eye. It will be especially valuable to those in the following job functions:

  • CSO (Chief Scientific Officer)
  • Chief Medical Officer and Medical Personnel
  • Scientists
  • Pharmacovigilence Personnel
  • Protocol Developers
  • Internal/External CRAs
  • Business Development Personnel

Course Description

This 90-minute accredited online training will provide an introduction and overview to the development of therapeutics for the treatment of ocular diseases which occur primarily in the posterior fundus of the eye. Emphasis will be placed on posterior fundus anatomy and diseases, principles of drug delivery to the back of the eye, clinical development and pathway to regulatory approval.

Organized by:

CfPA-The Center for Professional Advancement

Invited Speakers:

Bart Chapman, MD, MBA and Fellow of the American Academy of Ophthalmology

As a board certified physician with over 30 successful years in the biopharmaceutical and medical device industry Bart Chapman MD MBA has been involved in approved NDAs, BLAs and PMAs and directing clinical trials through all phases.

His role has varied from developing Phase I-IV protocols and implementing them to overseeing strategic marketing and regulatory compliance. He has been involved in designing and implementing MOPS which have included integrating protocol design and phase I- IV implementation with the launch and marketing of approved products.

As both an employee as well as a consultant to numerous pharmaceutical companies from Fortune 100 companies to small biotech companies, Dr. Chapman has a successful track record in developing strategic plans. In the process he has designed and implement GLP and GMP facilities.

Dr. Chapman has secured sophisticated SABs as well as participated in numerous leadership roles as both physician investigator as well as physician advisor for the development of ocular, infectious disease, diabetes, oncology and medical device therapeutics.

Deadline for Abstracts:

n/a

Registration:

Please click here for registration information.

E-mail:

sberg@cfpa.com

home

genetic news

bioinformatics

biotechnology

literature

journals

ethics

positions

events

sitemap